OpenAI has introduced a new AI model specifically designed for life sciences research, marking the company’s biggest push yet into scientific applications. The GPT-Rosalind model, named after DNA structure pioneer Rosalind Franklin, targets biochemistry, drug discovery, and translational medicine research.
The move comes as pharmaceutical companies and biotech firms increasingly turn to AI tools to speed up research and reduce the massive costs of drug development. Traditional drug discovery can take over a decade and cost billions of dollars, making AI acceleration particularly valuable for the industry.
What GPT-Rosalind can do
The new model goes beyond simple question-answering to handle complex research workflows. According to OpenAI, GPT-Rosalind can support several key research activities:
- Query scientific databases for relevant research
- Read and analyze the latest scientific papers
- Generate hypotheses based on existing evidence
- Plan experiments and suggest new research directions
- Connect with over 50 scientific tools and data sources
“By supporting evidence synthesis, hypothesis generation, experimental planning, and other multi-step research tasks, this model is designed to help researchers accelerate the early stages of discovery,” OpenAI said in a blog post.
Early partnerships with major companies
OpenAI is already working with several major players in the life sciences industry to test GPT-Rosalind across different research workflows. Partners include Amgen, Moderna, and Thermo Fisher Scientific, though the company hasn’t shared specific details about these collaborations.
The model is available as a research preview through ChatGPT, OpenAI’s Codex platform, and the company’s API for qualified customers. OpenAI is also launching a free Life Sciences research plugin for Codex that connects scientists to scientific tools and databases.
Part of OpenAI’s specialized model strategy
GPT-Rosalind represents OpenAI’s strategy of creating specialized versions of its core technology for specific industries. The company recently announced GPT-5.4-Cyber for cybersecurity work, following competitor Anthropic’s release of its Mythos AI model.
This approach allows OpenAI to compete more directly with specialized AI companies in lucrative sectors like healthcare and security, while building deeper relationships with enterprise customers who need domain-specific capabilities.